Renal osteodystrophy, a well-established chronic complication of dialysis patients and also a surrogate for quality of renal replacement therapy, is classified into high-turnover and low-turnover rate bone diseases. The former is mainly caused by secondary hyperparathyroidism, whereas the latter consists of aluminum intoxication and adynamic bone disease. According to the pathophysiology of renal osteodystrophy, manipulation of serum calcium and phosphate is critical for the management of dialysis patients to prevent and control this complication. The goal of management of renal osteodystrophy is not only to get good control of hyperparathyroidism, but also to avoid low-turnover rate bone diseases.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。